A total of 104 postmenopausal women were randomly assigned to different therapeutic regimens: (a) calcitonin, (b) estrogen/progestogen (HRT) plus calcitonin, (c) estrogen/progestogen (HRT), (d) and the control group. The bone mass of the lumbar vertebrae of all patients was assessed with a dual beam photon absorptiometer (Norland GD 153). The 73 patients who completed the 1-yr study showed that postmenopausal bone loss could be prevented by either estrogen/progestogen (HRT) or calcitonin. In addition, the combination of hormonel replacement therapy and calcitonin not only prevented postmenopausal bone loss but resulted in a significant 10% gain in bone mass (P <0.001).
|Number of pages||5|
|Journal||European Journal of Obstetrics and Gynecology and Reproductive Biology|
|Publication status||Published - Oct 23 1992|
- Bone loss
ASJC Scopus subject areas
- Obstetrics and Gynaecology
- Reproductive Medicine